Barclays
RPRX icon

Barclays’s Royalty Pharma RPRX Stock Holding History

Barclays’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.9M Sell
622,433
-96,182
-13% -$5.01M 0.01% 878
2026
Q1 		$34.5M Buy
718,615
+176,551
+33% +$7.73M 0.01% 867
2025
Q4 		$20.9M Sell
542,064
-10,495
-2% -$400K 0.01% 1234
2025
Q3 		$19.5M Buy
552,559
+213,197
+63% +$7.72M ﹤0.01% 1245
2025
Q2 		$12.2M Sell
339,362
-27,868
-8% -$923K ﹤0.01% 1430
2025
Q1 		$11.4M Buy
367,230
+3,922
+1% +$124K ﹤0.01% 1313
2024
Q4 		$9.27M Buy
363,308
+54,421
+18% +$1.44M ﹤0.01% 1630
2024
Q3 		$8.74M Buy
308,887
+43,339
+16% +$1.2M ﹤0.01% 1577
2024
Q2 		$7M Sell
265,548
-19,341
-7% -$536K ﹤0.01% 1347
2024
Q1 		$8.65M Sell
284,889
-117,229
-29% -$3.46M ﹤0.01% 1496
2023
Q4 		$11.3M Sell
402,118
-911,961
-69% -$25.1M ﹤0.01% 1433
2023
Q3 		$35.7M Buy
1,314,079
+210,414
+19% +$6.25M 0.02% 590
2023
Q2 		$33.9M Buy
1,103,665
+670,204
+155% +$22.7M 0.02% 572
2023
Q1 		$15.6M Buy
433,461
+31,271
+8% +$1.16M 0.01% 962
2022
Q4 		$15.9M Buy
402,190
+181,497
+82% +$7.58M 0.01% 996
2022
Q3 		$8.87M Buy
220,693
+9,914
+5% +$423K 0.01% 903
2022
Q2 		$8.86M Buy
210,779
+25,219
+14% +$1.03M 0.01% 1064
2022
Q1 		$7.23M Buy
+185,560
New +$7.29M 0.01% 1053

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Barclays's RPRX Position: Q2 2026 in Review

Barclays reduced its Royalty Pharma (RPRX) stake by 13% in Q2 2026, selling an estimated $5.01M and leaving 622,433 shares worth $34.9M. The position accounts for 0.01% of the portfolio, ranked #878.

Barclays first reported a position in RPRX in Q1 2022 and has held it in 18 quarters since. The position peaked at $35.7M in Q3 2023. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Barclays held 622,433 shares of Royalty Pharma worth $34.9M as of Q2 2026.
  • Barclays sold 96,182 Royalty Pharma shares in Q2 2026, an estimated $5.01M.
  • Royalty Pharma made up 0.01% of Barclays's portfolio in Q2 2026, its #878 holding.
  • Barclays first reported a position in Royalty Pharma in Q1 2022 and has held it in 18 quarters since.
  • Barclays's Royalty Pharma position peaked at $35.7M in Q3 2023.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.